Log in

Relevant bibliographies by topics / Extracellular Matrix; congresses

Contents

Journal articles
Books
Book chapters
Conference papers

Academic literature on the topic 'Extracellular Matrix; congresses'

Author: Grafiati

Published: 4 June 2021

Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Extracellular Matrix; congresses.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Extracellular Matrix; congresses"

1

Kuyvenhoven, Johan, Bart van Hoek, Eric Blom, Wim van Duijn, Roeland Hanemaaijer, Jan Verheijen, Cornelis Lamers, and Hein Verspaget. "Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma." Thrombosis and Haemostasis 89, no. 04 (2003): 718–25. http://dx.doi.org/10.1055/s-0037-1613578.

Full text

Abstract:

SummaryMatrix metalloproteinases (MMPs) have the ability to degrade basement membranes and may thus play an important role in extracellular matrix turnover in liver fibrosis and carcinogene-sis. Serum levels of MMPs have been suggested as diagnostic markers in these processes.We measured serum MMP-2 and MMP-9 by ELISA in 91 patients with chronic liver disease, including 25 patients with hepatocellular carcinoma (HCC), and in 60 controls.MMP-2 was significantly higher in patients with chronic liver disease compared to controls, and increased with Child-Pugh class. There was a significant correlation between MMP-2 and liver function (bilirubin, albumin, and prothrombin time), and a strong opposite correlation between MMP-9 and these parameters.MMP-2 levels in patients with HCC were significantly higher than in controls, but comparable to patients with chronic liver disease without this malignancy. MMP-9 yielded no significant differences between patients with or without HCC and controls.Serum MMP-2 and to a lesser extent MMP-9 correlate with the severity of liver disease and may reflect changes in extracellular matrix remodeling. Due to a considerable overlap in patients with chronic liver disease with or without HCC, MMP-2 and MMP-9 can not be used as a diagnostic marker for HCC.Theme paper: Part of this paper was originally presented at the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September, 2002.

APA, Harvard, Vancouver, ISO, and other styles

2

Lynn, David, Andrew Lloyd, Caroline O’Shea, and Michael Duffy. "The ADAMs family of proteins: from basic studies to potential clinical applications." Thrombosis and Haemostasis 89, no. 04 (2003): 622–31. http://dx.doi.org/10.1055/s-0037-1613568.

Full text

Abstract:

SummaryThe ADAMs are a family of membrane proteins possessing a disintegrin and metalloprotease domain. Currently,34 members are known to exist. Approximately 50% of the ADAMs contain a metalloprotease-like domain and some of these have been shown to possess protease activity. Most of the protein substrates identified to date for ADAMs are either integral membrane or extracellular matrix (ECM) proteins. In addition to hydrolysing proteins, a number of ADAMs bind to integrins. The attachment to integrins occurs via the disintegrin domain. Since the ADAMs can play a role in both proteolysis and adhesion, they have been implicated in a variety of biological processes such as sperm-egg fusion, somatic cell-cell adhesion, ecto-domain shedding, myoblast fusion and development. Altered expression of certain ADAMs has been associated with a number of diseases including asthma, arthritis, Alzheimer’s disease, atherosclerosis and cancer.Theme paper: Part of this paper was originally presented at the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September, 2002.

APA, Harvard, Vancouver, ISO, and other styles

3

Schanstra, Joost, Johan Duchene, Laurence Desmond, Eric Neau, Denis Calise, Serge Estaque, Jean-Pierre Girolami, and Jean-Loup Bascands. "The protective effect of angiotensin converting enzyme inhibition in experimental renal fibrosis in mice is not mediated by bradykinin B2 receptor activation." Thrombosis and Haemostasis 89, no. 04 (2003): 735–40. http://dx.doi.org/10.1055/s-0037-1613580.

Full text

Abstract:

SummaryUnilateral ureteral obstruction (UUO) is an animal model of accelerated renal tubulointerstitial fibrosis. We have recently shown, using this model, that mice lacking the bradykinin B2-receptor (B2-/- ) were more susceptible than control animals to the development of tubulointerstitial fibrosis. Angiotensin converting enzyme (ACE) inhibition slows down UUO-induced renal fibrosis. Since ACE-inhibition increases bradykinin and decreases angiotensin II concentrations we have verified if bradykinin is involved in the antifibrotic effects of ACE-inhibition using the UUO-model and B2-/- mice. Surprisingly, although ACE-inhibition significantly reduced renal fibrosis, no difference was observed between the degree of tubulointerstitial fibrosis, macrophage infiltration and cell proliferation between ACE-inhibitor treated B2+/+ and B2-/- mice suggesting the absence of a role of the B2-receptor in the antifibrotic effects of ACE-inhibition. This was confirmed at the level of bradykinin-induced activity of enzymes involved in the degradation of the extracellular matrix. However in both mouse strains, ACE-inhibitors were more efficient than AT1 receptor antagonists.Theme paper: Part of this paper was originally presented at the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September, 2002.

APA, Harvard, Vancouver, ISO, and other styles

4

Dobrota, R., S. Jordan, P. Juhl, B. Maurer, M. O. Becker, C. Mihai, A. C. Bay-Jensen, M. Karsdal, A. S. Siebuhr, and O. Distler. "OP0252 CIRCULATING COLLAGEN TURNOVER MARKERS ARE SPECIFICALLY CHANGED IN VERY EARLY SYSTEMIC SCLEROSIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 159.1–159. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5683.

Full text

Abstract:

Background:Timely diagnosis of patients with very early systemic sclerosis (veSSc) is essential for their personalized and optimal management. We hypothesise that changes in serum-based extracellular matrix (ECM) turnover biomarkers are already detectable in patients with veSSc, even before occurrence of specific clinical signs.Objectives:To investigate circulating ECM turnover markers as potential biomarkers for veSSc.Methods:Patients with veSSc, n=42, defined as presence of Raynaud’s syndrome and at least one of puffy fingers, positive antinuclear antibodies or pathological nailfold capillaroscopy, who did not meet any classification criteria for SSc, were compared to healthy controls (HC, n=29). Longitudinal assessment, data and sera collection were conducted by EUSTAR standards. ECM-degradation (BGM, C3M, C4M, C6M) and ECM-formation biomarkers (PRO-C3, PRO-C4, PRO-C5) were measured in serum using ELISA assays. The statistical analyses included Mann-Whitney U, Spearman correlation and ROC analysis. Using Kaplan-Meier plots and univariable Cox regression, we explored if biomarkers can predict progression towards definite SSc (fulfillment of ACR/EULAR criteria or minimum two points increase in the criteria score) during the longitudinal follow-up.Results:Compared to HC, veSSc patients showed a deregulated turnover of type III and IV collagen, with higher degradation (higher C3M, C4M, both p<0.0001 and PRO-C3, p=0.004, Figure 1a, resulting in lower turnover ratios PRO-C3/C3M and PRO-C4/C4M, both p<0.0001). The biglycan degradation biomarker BGM was also higher in veSSc (p=0.006), whereas the degradation biomarker for type VI collagen, C6M, was lower than in HC (p=0.002). In the ROC analysis, biomarkers of type III and IV collagen distinguished between veSSc and HC: C3M, AUC=0.95, p<0.0001; C4M, AUC=0.97, p<0.0001; turnover ratios PRO-C3/C3M, AUC=0.80, p<0.0001; PRO-C4/C4M, AUC=0.97; p<0.0001 (Figure 1b).Median follow up was 4.5 years (range 0.5-7.9 years), mean age was 50±2.2 years, 88% female gender, 24% with puffy fingers, 92% were ANA positive, 64% had an abnormal capillaroscopy, none had organ involvement or skin fibrosis. 14/42 veSSc patients fulfilled the ACR/EULAR classification criteria at follow-up (time to fulfilment of criteria ranged between 0.5 and 6.8 years from inclusion) and in addition, 18/42 veSSc patients gained at least two classification criteria-points. This resulted in 14, respectively 18 progressors for the longitudinal analysis. However, in univariable Cox regression, the baseline levels of the markers did not predict progression over time.Conclusion:ECM turnover is already altered in veSSc patients compared to HC. Biomarkes of type III and IV collagen distinguished between veSSc patients and HC, which may indicate them as potential biomarkers for the detection of veSSc in addition to the established immunological and capillaroscopic criteria.Disclosure of Interests:Rucsandra Dobrota: None declared, Suzana Jordan: None declared, Pernille Juhl Employee of: Nordic Bioscience, Britta Maurer Grant/research support from: AbbVie, Protagen, Novartis, congress support from Pfizer, Roche, Actelion, and MSD, Speakers bureau: Novartis, Mike O. Becker: None declared, Carina Mihai: None declared, Anne-Christine Bay-Jensen Shareholder of: Nordic Bioscience A/S, Employee of: Full time employee at Nordic Bioscience A/S., Morten Karsdal Shareholder of: Nordic Bioscience A/S., Employee of: Full time employee at Nordic Bioscience A/S., Anne Sofie Siebuhr Employee of: Nordic Bioscience, Oliver Distler Grant/research support from: Grants/Research support from Actelion, Bayer, Boehringer Ingelheim, Competitive Drug Development International Ltd. and Mitsubishi Tanabe; he also holds the issued Patent on mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143)., Consultant of: Consultancy fees from Actelion, Acceleron Pharma, AnaMar, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer, CSL Behring, Catenion, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, GSK, Glenmark Pharmaceuticals, Inventiva, Italfarmaco, iQvia, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Roche, Sanofi and UCB, Speakers bureau: Speaker fees from Actelion, Bayer, Boehringer Ingelheim, Medscape, Pfizer and Roche

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Extracellular Matrix; congresses"

1

Society for Matrix Research. International Congress. Normal matrix and pathological conditions: 2nd International Congress of the Society for Matrix Research. Stuttgart: G. Fischer, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

1942-, Reddi A. H., ed. Extracellular matrix: Structure and function : proceedings of the Dow-UCLA Symposium, held in Keystone, Colorado, April 22-29, 1984. New York: A.R. Liss, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Yousuf, Ali S., ed. Cell mediated calcification and matrix vesicles: Proceedings of the IV International Conference on Matrix Vesicles, Cambridge, 1-5 July 1985. Amsterdam: Excerpta Medica, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Matrix Metalloproteinase Conference (1989 Sandestin Beach, Fla.). Matrix metalloproteinases and inhibitors: Proceedings of the Matrix Metalloproteinase Conference held at Sandestin Beach, FL, September 11-15, 1989. Edited by Birkedal-Hansen Henning. Stuttgart: G. Fischer Verlag, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Society for Matrix Research. International Congress. Extracellular matrix and groundregulation system in health and disease. Stuttgart: Gustav Fischer, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

International, EBSA Symposium (2nd 1988 Gwatt Switzerland). Cytoskeletal and extracellular proteins: Structure, interaction, and assembly. Berlin: Springer-Verlag, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Inhibitors of Metalloproteinases Conference (1996 Banff, Alta.). Tissue inhibitors of metalloproteinases in development and disease: Proceedings of the Inhibitors of Metalloproteinases Conference, Banff, Alberta, Canada, September 25-29, 1996. Edited by Hawkes Susan P, Edwards Dylan R, and Khokha Rama. Australia: Harwood Academic, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Johnson, A. Wagoner. Mechanobiology of Cell-Cell and Cell-Matrix Interactions. Boston, MA: Springer Science+Business Media, LLC, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hikaru, Koide, and Hayashi T, eds. Extracellular matrix in the kidney: 6th International Symposium on Basement Membrane, Shizuoka, May 29-June 1, 1993. Basel: Karger, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

M, Rabie A. Bakr, and Urist Marshall R, eds. Bone formation and repair: Proceedings of the International Symposium on Formation and Repair of Mineralized Extracellular Matrix, Hong Kong, 18-19 October, 1996. Amsterdam [Netherlands]: Elsevier, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Extracellular Matrix; congresses"

1

Williams, David. "Extracellular matrix changes in canine chronic superficial keratitis." In BSAVA Congress Proceedings 2017, 514. British Small Animal Veterinary Association, 2017. http://dx.doi.org/10.22233/9781910443439.68.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Extracellular Matrix; congresses"

1

Januskevicius, Andrius, Ieva Janulaityte, Reinoud Gosens, Virginija Kalinauskaite-Zukauske, Rokas Stonkus, and Kestutis Malakauskas. "Eosinophils contribute to extracellular matrix remodeling by enhancing pulmonary fibroblasts proliferation, differentiation and extracellular matrix proteins production in asthma." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa968.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

de Hilster, Roderick H. J., Marnix R. Jonker, Wim Timens, Prashant K. Sharma, Martin C. Harmsen, Machteld N. Hylkema, and Janette K. Burgess. "Human lung stiffness and viscoelasticity replicated in extracellular matrix hydrogels." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa585.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Papakonstantinou, Eleni, Ioannis Bonovolias, George Karakiulakis, Michael Tamm, Renaud Louis, Branislava Milenkovic, Wim Boersma, et al. "Extracellular matrix glycosaminoglycans can predict severity and outcome in COPD." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa4271.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Saito, T., Y. Morita, and E. Nakamachi. "Effect of the Gradient Magnetic Field Stimulation on Extracellular Matrix Synthesis of Chondrocyte." In ASME 2016 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/imece2016-66419.

Full text

Abstract:

Many researchers tried to improve mechanical properties of the cultured cartilage by physical stimulation. However, its mechanical properties were insufficient. Extracellular matrix structure similar to natural articular cartilage is necessary to form mechanical properties of cultured cartilage. Gradient magnetic field was expected to change pericellular microenvironment associated with local chondrocyte activity. We investigated the effects of gradient magnetic field on chondrocyte activity and extracellular matrix structure. Chondrocytes were cultured under the gradient magnetic field for 7 days, and stimulation time was 12 hours in a day. Intensity of magnetic field was 1.5 mT in the center of a dish. Intensity of gradient magnetic field was 0.03 mT/mm. Chondrocytes were cultured under the uniform magnetic field for control group. The synthesized extracellular matrix in a dish was observed with second harmonic generation, and GAG amount was measured after cultivation. GAG amount in the gradient group was almost same with that in the uniform group. According to SHG image, the area and the thickness of extracellular matrix increased with increasing intensity of magnetic field in the gradient group. This study showed that the gradient magnetic field stimulation formed difference in extracellular matrix structure which depends on local chondrocyte activity.

APA, Harvard, Vancouver, ISO, and other styles

5

Jandl, Katharina, Leigh M. Marsh, Julia Hoffmann, Ayse Ceren Mutgan, Oliver Baum, Wilhelm Bloch, Katharina Sinn, et al. "Basement membrane, a specialized extracellular matrix, shapes endothelial function in IPAH." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1488.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Collum, S., T. Weng, A. Hernandez, T. Mertens, N. Chen, A. Guha, K. Youker, et al. "Alternative Polyadenylation(APA) modulates extracellular matrix deposition in pulmonary hypertension." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.lsc-1044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mueller, Catharina, Annika Andersson-Sjöland, Hans Henrik Schultz, Claus B. Andersen, Martin Iversen, and Gunilla Westergren-Thorsson. "Mapping of extracellular matrix proteins in different compartments of transplanted lungs." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2543.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Jessen, Henrik, Nils Hoyer, Sarah Rønnow, Morten Karsdal, Diana Leeming, Jannie Sand, and Saher Shaker. "Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Almendros, Isaac, Jorge Otero, Bryan Falcones, Esther Marhuenda, Daniel Navajas, and Ramon Farre. "Lung extracellular matrix hydrogel for 3D bioprinting of lung mesenchymal stem cells." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3859.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Carpaij, Orestes, A. W. M. Goorsenberg, D. M. De Bruin, R. M. Van Den Elzen, M. C. Nawijn, H. A. M. Kerstjens, M. Van Den Berge, J. T. Annema, J. K. Burgess, and P. I. Bonta. "Optical coherence tomography (OCT) detects collagen within the airway wall extracellular matrix." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!